Related Experiment Video
Updated: May 29, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
[Anti-angiogenic strategies in glioblastoma]
1Service de neurologie, hôpital Côte-de-Nacre, CHU de Caen, 14033 Caen cedex, France. guillamo-js@chu-caen.fr.
Introduction:
Glioblastoma, a highly angiogenic tumor, has poor prognosis despite aggressive conventional therapies combining surgery, chemotherapy and radiotherapy. Anti-angiogenic strategies that have recently come to the clinic, are the most promising therapeutic approaches for these tumors.
State Of Art:
Tumor hypoxia is the main trigger of angiogenesis processes driven primarily by vascular endothelial growth factor (VEGF). Clinical data indicate that inhibitors of VEGF such as bevacizumab or VEGF receptors such as tyrosine kinase inhibitors are of potential interest in the treatment of recurrent glioblastoma, with an acceptable toxicity. However, despite high rate of initial radiological response and rapid clinical improvement in about half of patients, therapeutic failure is the rule. Mechanisms of resistance remain poorly understood but an invasive phenotype and alternative angiogenesis factors may contribute to tumor escape.
Conclusions And Perspectives:
Anti-angiogenic strategies already play an important role in the management of recurrent glioblastoma. However, optimal combination and schedules of angiogenic inhibitors with radiotherapy and chemotherapy remain to be established. Important randomized clinical trials currently investigate therapeutic combinations for newly diagnosed glioblastoma.
Insights
Anti-angiogenic therapies targeting vascular endothelial growth factor (VEGF) show promise for glioblastoma. However, resistance mechanisms necessitate further research into optimal combinations with chemotherapy and radiotherapy.
Area of Science:
- Oncology
- Cancer Biology
- Neuro-oncology
Context:
- Glioblastoma is a highly angiogenic brain tumor with a poor prognosis.
- Conventional therapies (surgery, chemotherapy, radiotherapy) have limited efficacy.
- Anti-angiogenic strategies targeting vascular endothelial growth factor (VEGF) are emerging as promising treatments.
Purpose:
- To review the role of anti-angiogenic strategies in glioblastoma treatment.
- To discuss the challenges and mechanisms of resistance to anti-angiogenic therapies.
- To highlight ongoing research and future directions in glioblastoma therapy.
Summary:
- Anti-angiogenic therapies, particularly those targeting VEGF, are increasingly important in managing recurrent glioblastoma.
- While initial responses can be significant, therapeutic failure is common due to poorly understood resistance mechanisms, potentially involving tumor invasiveness and alternative angiogenic factors.
- Optimizing combinations of angiogenic inhibitors with chemotherapy and radiotherapy is crucial for improving patient outcomes.
Impact:
- Anti-angiogenic therapies represent a significant advancement in glioblastoma treatment.
- Understanding resistance mechanisms is key to developing more effective therapeutic strategies.
- Ongoing clinical trials are vital for establishing optimal treatment regimens for both recurrent and newly diagnosed glioblastoma.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:10Mechanism of Angiogenesis